Craig joins Anthera with over 20 years of experience in the pharmaceutical and healthcare industries. He has a proven track record in product development, global brand management, product positioning, access and reimbursement, including the strategic marketing of a number of industry-leading drugs.

Prior to Anthera, Craig was the Chief Operating Officer for Tetraphase Pharmaceuticals where he oversaw the development and implementation of the marketing, access & reimbursement and sales strategy as well as the business development and the commercial manufacturing for the company.

Prior to Tetraphase, he served as Chief Commercial Officer for Trius Therapeutics through the acquisition of Trius by Cubist Pharmaceuticals, Inc. in September 2013. Craig led the planning of the commercial strategy, was actively involved in negotiating a regional partnership with Bayer as well as the actively involved in the acquisition of the company by Cubist. During his tenure he participated in three company financing raising $115 MM.

Prior to Trius, Mr. Thompson served in various global and U.S. commercial roles at Pfizer Inc. from 2003 to December 2010 ultimately serving as Vice President of Marketing for Pfizer’s Specialty Care Business Unit, where he was directly responsible for the U.S. commercial strategy for a portfolio of products with more than $1.5 billion in annual U.S. sales. From 1992 to 2003, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc., where he most notably worked on commercial planning and marketing activities for the company’s major cardiovascular brands.

Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame.

Dr. Shanahan, 68, served as the Chief Medical Officer of Arena Pharmaceuticals, Inc., from 2004 to June 2016 and served as its Senior Vice President from June 2010 to June 2016. Dr. Shanahan also served as Vice President of Arena Pharmaceuticals Inc. from March 2004 to June 2010.

At Arena Pharmaceuticals Inc., Dr. Shanahan was involved in all aspects of preclinical and clinical development, from phase 1 through NDA filing and approval, of lorcaserin, a selective 5-HT2C agonist for weight management, as well as multiple other programs in a range of therapeutic areas through phase 1 and phase 2.

He served as Tanox Inc.’s Chief Medical Officer from August 2000 until March 2004, developing several monoclonal antibodies for allergy, inflammation and HIV through phase 1 and phase 2.

Dr. Shanahan served as Vice President, Drug Development of Isis Pharmaceuticals from 1994 to August 2000, working on anti-inflammatory/immunomodulatory antisense therapeutics in phase 1-3. Prior to that, he was Director of Clinical Research at Pfizer Central Research where he directed the clinical development of new anti-inflammatory pharmacologic agents from 1990 to 1994.

At Searle Research and Development, he held Associate Director and Director of Clinical Research positions where he developed and monitored clinical studies related to anti-inflammatory, gastro-protective, anti-HIV, and antineoplastic pharmacologic agents from 1988 to 1990. In addition, at the University of Connecticut School of Medicine he held various positions in the Division of Rheumatology including a full time faculty position as Assistant Professor and a voluntary and part-time position as Clinical Associate Professor.

Dr. Shanahan holds an A.B. degree from Dartmouth College, an M.D. degree from the University of California, San Francisco, and a J.D. degree from Loyola University, Chicago.

With over 30 years of experience in the biotech industry, Chuck is a drug developer with unique scientific understanding and broad operational experience for protein based pharmaceutical products. From his scientific background, he has gained specialized expertise in process development and technology transfer, smoothing the transitions from R&D to production, and clinical product manufacturing to commercialization. With a significant early portion of his career as a Scientist at Genentech and Staff Scientist at Bayer, Chuck subsequently held management positions with increasing levels of responsibility at Onyx, BioMarin, Cell Genesys, Coherus Biosciences, NGM Biopharmaceuticals and Anthera Pharmaceuticals. He has a bachelor’s degree in biology and chemistry, a masters in chemistry and a doctorate in biochemistry.
Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics’ initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix’s initial product, Ventavis® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
Ms. Liu previously served as Anthera’s Vice President, Finance since January 2011. Prior to that, she served Anthera as Corporate Controller since October 2007. Ms. Liu joined the company as Director of Finance in April 2007. Prior to joining Anthera, Ms. Liu served as SEC Reporting and Technical Accounting Manager at Renovis, Inc., a clinical-stage pharmaceutical company, from October 2005 to March 2007. Ms. Liu has been a Certified Public Accountant since 2007 and worked at the audit and assurance practice of Ernst & Young, LLP. from 2000 to 2005, focusing primarily in the life science industry. Ms. Liu holds a B.S. in business administration with a concentration in accounting from San Francisco State University.
Dr. Martin previously served as Anthera’s Vice President, Nonclinical and Translational Sciences. Dr. Martin joined Anthera as the Senior Director of Clinical and Translational Sciences in March 2010 after an over 14-year research tenure from October 1996 to March 2010 at Roche Pharmaceuticals in both drug discovery and drug development. Counting her time at Roche, Dr. Martin has over 20 years of experience in the pharmaceutical industry, including a 4-year postgraduate research position from May 1992 through October 1996 at Wellcome/GlaxoWellcome Research Laboratories in the UK. Dr. Martin holds a B.A. in Natural Sciences from Cambridge University, UK and a Ph.D. in Pharmacology from King’s College University of London, UK.
Print Friendly